Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Other 1

Conditions

Neoplasms 7Lung Neoplasms 6Colorectal Neoplasms 5Prostatic Neoplasms 3Smoking Cessation 2Neoplasm Metastasis 2Colonic Neoplasms 2Uveal Melanoma 1Stomach Neoplasms 1Solitary Pulmonary Nodule 1Retroviridae Infections 1Pulmonary Disease, Chronic Obstructive 1Pancreatic cancer, adult 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasm, Residual 1Multiple Myeloma 1Motor Activity 1Lymphoma 1Inflammation 1Glioblastoma 1Esophageal Neoplasms 1Dyspnea 1Disease 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Cardiovascular Diseases 1Cardiotoxicity 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Dexamethasone 239Lenalidomide 145daratumumab 124Bortezomib 102pomalidomide 87Calcium Dobesilate 76carfilzomib 74Cyclophosphamide 70Specimen Handling 42isatuximab 40Biopsy 40belantamab mafodotin 37fludarabine 36Magnetic Resonance Spectroscopy 35talquetamab 29dexamethasone acetate 27dexamethasone 21-phosphate 27Melphalan 27iberdomide 26auricularum 26ixazomib 22fludarabine phosphate 22selinexor 21elotuzumab 21Whole-Body Irradiation 14X-Rays 13tocilizumab 12venetoclax 11Mycophenolic Acid 10trametinib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × Hematologic Tests × 1 year × Clear all
NCT04827563 2026-03-04

Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

University of Chicago

Terminated
50 enrolled
OtherPlasma cell

Dyspnea, Multiple Myeloma, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡